March 19, 2017

MultiplexDX Launches FullRNALook - the Simplest and Most Robust RNA FISH on the Market

MultiplexDX proudly announces the availability of a new FullRNALook – innovative, highly reliable and cost-effective RNA FISH solution with the simplest protocol for cancer diagnostics market.  Based on proprietary MultiplexDX technology FullRNALook incorporates many refinements and enhancements to enable the highest quality and fastest results without special equipment since entire protocol runs at ROOM TEMPERATURE and all reagents could be also stored at room temperature.

 Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:  “FullRNALook is great for RNA integrity and RNA FISH specificity assessment. Probes included in kit could be used as RNA FISH standards and normalizers. FastRNAlook kit FISH results could be designed for detection in 4 fluorescence microscopy channels (Cy2, Cy3, Cy5 and Cy7) allowing additional versatility, complementing your custom assays.”

 FullRNALook is compatible with all RNA FISH protocols (ACD, Stellaris, Affymetrix, Ventana, PerkinElmer, Exiqon) and automated tissue processors (Ventana, Biogenex). For further information you’re welcome to visit FullRNALook product page on our website

To check all the benefits of FullRNALook you’re welcome to order a FREE product sample. Just use our contact form and don’t hesitate to contact us with any queries regarding the product!

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News